Aroa Biosurgery (ASX:ARX) Beneish M-Score: -2.61 (As of Jun. 26, 2026)


ASX:ARX Aroa Biosurgery Ltd ASX:ARX
62 GF Score
Price A$0.59
GF Value A$0.80
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Aroa Biosurgery Beneish M-Score?

Aroa Biosurgery ASX:ARX +0.85% 62 Beneish M-Score is -2.61 as of Jun. 26, 2026. GuruFocus rates ASX:ARX with a GF Score™ of 62/100 and a GF Value™ of A$0.80 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 766 Medical Devices & Instruments companies, Aroa Biosurgery ranks better than 53.39% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.61 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Aroa Biosurgery's Beneish M-Score or its related term are showing as below:

ASX:ARX' s Beneish M-Score Range Over the Past 10 Years
Min: -2.79   Med: -2.48   Max: -1.27
Current: -2.61

During the past 7 years, the highest Beneish M-Score of Aroa Biosurgery was -1.27. The lowest was -2.79. And the median was -2.48.


Aroa Biosurgery Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Aroa Biosurgery's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery Beneish M-Score Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial -1.27 -2.48 -2.79 -2.41 -2.61

Aroa Biosurgery Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.79 0.00 -2.41 0.00 -2.61

ASX:ARX vs ABT, SYK, MDT: Beneish M-Score Comparison

For the Medical Devices subindustry, Aroa Biosurgery's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aroa Biosurgery Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Aroa Biosurgery's Beneish M-Score falls into.


ASX:ARX
62GF Score
Aroa Biosurgery Ltd ASX:ARX
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aroa Biosurgery Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Aroa Biosurgery for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1075+0.528 * 1.0024+0.404 * 1.0653+0.892 * 1.1252+0.115 * 0.9238
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9276+4.679 * -0.063656-0.327 * 1.2208
=-2.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was A$18.49 Mil.
Revenue was A$86.60 Mil.
Gross Profit was A$74.07 Mil.
Total Current Assets was A$64.44 Mil.
Total Assets was A$100.60 Mil.
Property, Plant and Equipment(Net PPE) was A$17.27 Mil.
Depreciation, Depletion and Amortization(DDA) was A$4.38 Mil.
Selling, General, & Admin. Expense(SGA) was A$63.60 Mil.
Total Current Liabilities was A$13.52 Mil.
Long-Term Debt & Capital Lease Obligation was A$4.08 Mil.
Net Income was A$3.90 Mil.
Gross Profit was A$1.51 Mil.
Cash Flow from Operations was A$8.79 Mil.
Total Receivables was A$14.84 Mil.
Revenue was A$76.97 Mil.
Gross Profit was A$65.99 Mil.
Total Current Assets was A$61.96 Mil.
Total Assets was A$98.94 Mil.
Property, Plant and Equipment(Net PPE) was A$19.54 Mil.
Depreciation, Depletion and Amortization(DDA) was A$4.49 Mil.
Selling, General, & Admin. Expense(SGA) was A$60.93 Mil.
Total Current Liabilities was A$9.36 Mil.
Long-Term Debt & Capital Lease Obligation was A$4.81 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(18.489 / 86.603) / (14.837 / 76.969)
=0.213491 / 0.192766
=1.1075

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(65.989 / 76.969) / (74.071 / 86.603)
=0.857345 / 0.855294
=1.0024

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (64.442 + 17.271) / 100.604) / (1 - (61.955 + 19.544) / 98.939)
=0.187776 / 0.17627
=1.0653

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=86.603 / 76.969
=1.1252

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(4.492 / (4.492 + 19.544)) / (4.38 / (4.38 + 17.271))
=0.186886 / 0.2023
=0.9238

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(63.597 / 86.603) / (60.931 / 76.969)
=0.734351 / 0.79163
=0.9276

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((4.082 + 13.516) / 100.604) / ((4.814 + 9.363) / 98.939)
=0.174923 / 0.14329
=1.2208

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(3.901 - 1.511 - 8.794) / 100.604
=-0.063656

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Aroa Biosurgery has a M-score of -2.61 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.61 mean?
Aroa Biosurgery (ASX:ARX) has a Beneish M-Score of -2.61 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Aroa Biosurgery and its competitors. According to the industry distribution chart, Aroa Biosurgery ranks #357 out of 766 companies in the Medical Devices & Instruments industry, placing it in the top 46.6%.
Is Aroa Biosurgery's Beneish M-Score too high?
Aroa Biosurgery's current Beneish M-Score is -2.61. Based on the distribution chart, Aroa Biosurgery ranks #357 out of 766 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aroa Biosurgery has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Beneish M-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #357 out of 766 companies for Beneish M-Score. This puts Aroa Biosurgery in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Aroa Biosurgery and its competitors. Aroa Biosurgery's current Beneish M-Score is -2.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.80, compared to a current price of A$0.59 — trading 26.3% below its estimated fair value. The current Beneish M-Score is -2.61. Aroa Biosurgery's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Beneish M-Score is -2.61 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?

Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued. The current stock price of A$0.59 is trading 26.3% below its estimated GF Value™ of A$0.80. GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.

Key valuation signals for ASX:ARX:

  • Beneish M-Score: -2.61
  • GF Value™: A$0.80 vs. price of A$0.59 (26.3% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aroa Biosurgery Business Description

Other Exchanges AROAF:USA
Address 64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
62GF Score

Get the complete analysis for ASX:ARX

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.59
Price
A$0.80
GF Value